Abstract
ORIGINAL ARTICLE, p 651 The comprehensive systematic review of 106 randomized controlled trials for rosacea involving 13 631 participants by van Zuuren and Fedorowicz1 in this issue of the BJD provides valuable evidence as to the effectiveness of established and new treatments for patients with rosacea. Rosacea is a poorly understood yet common facial skin disorder often associated with ocular symptoms. The term ‘rosacea’ is commonly used by dermatologists to describe patients who have a constellation of symptoms and signs ranging from frequent flushing to hypertrophic nasal enlargement. While the classification of rosacea into subtypes2 helped clinicians to develop a strategy of disease management for their patients,3 the spectrum of clinical features included under the title ‘rosacea’ made it likely that more than one pathogenic pathway would be operative in this disorder. This is reflected in the wide variety of therapies used for rosacea ranging from surgery (for rhinophyma) to topical and systemic antibiotics [for papulopustular rosacea (PPR)].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
